Clinical trial
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus (or Pre-diabetes) and Heart Failure (SUGAR-DM-HF)
NCT03485092 is registered in ClinicalTrials.gov with NHS Greater Glasgow and Clyde as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus (or Pre-diabetes) and Heart Failure (SUGAR-DM-HF)
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 16, 2018
- Completion date
- March 28, 2020
- Enrollment
- 105 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.